Misoprostol for Postpartum Hemorrhage

Project Overview

In many countries around the world, women give birth at home, often with only a family member or traditional birth attendant by their side. For these women, and for those giving birth in a health facility without reliable electricity, refrigeration, or IV therapy, misoprostol may be the best option for preventing and treating excessive bleeding, or postpartum hemorrhage (PPH), one of the leading causes of maternal death globally. Misoprostol is available in tablet form, can be stored without refrigeration, and does not require injection or specialized skills to administer. Extensive research has shown misoprostol is safe and effective in preventing and treating PPH in health facilities and in community and home-birth settings.

As part of a longstanding partnership with Gynuity Health Projects, the FCI Program of MSH raises the visibility of misoprostol as an important, evidence-based intervention to treat and prevent PPH. The FCI Program of MSH shares the latest research findings with key global and national stakeholders and builds the capacity of advocates to influence policy change that promotes wider understanding, use, and acceptance of misoprostol for PPH in developing countries.

To learn more about misoprostol:

Initiatives

Project Team

Printer Friendly VersionPDF